Armata adds Gilmer to governance committee, $5k fee
Armata Pharmaceuticals, Inc. filed an amended report to update details about new director Dr. Daniel Gilmer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K/A
Rhea-AI Filing Summary
Armata Pharmaceuticals, Inc. filed an amended report to update details about new director Dr. Daniel Gilmer. The amendment explains that, effective June 24, 2026, the Board appointed Dr. Gilmer to its Nominating and Corporate Governance Committee. He will receive a $5,000 cash retainer for this committee role under the 2026 non-employee director compensation program, with the amount pro-rated based on his appointment date. All other information from the original report about his appointment to the Board remains unchanged.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Committee cash retainer: $5,000
Committee appointment effective date: June 24, 2026
Amendment filing date: April 24, 2026
3 metrics
Committee cash retainer
$5,000
Annual cash retainer for Nominating and Corporate Governance Committee service in 2026
Committee appointment effective date
June 24, 2026
Effective date of Dr. Gilmer’s service on Nominating and Corporate Governance Committee
Amendment filing date
April 24, 2026
Date referenced for the amended report under the Exchange Act
Key Terms
Nominating and Corporate Governance Committee, non-employee directors, proxy statement, cash retainer, +1 more
5 terms
Nominating and Corporate Governance Committee financial
"the Board appointed Dr. Gilmer to serve on the Nominating and Corporate Governance Committee of the Board"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
non-employee directors financial
"the compensation program for non-employee directors described in the Company’s proxy statement"
Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.
proxy statement regulatory
"described in the Company’s proxy statement dated April 27, 2026 for the Company’s 2026 annual meeting"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
cash retainer financial
"his cash retainer for his service as a member of the Nominating and Corporate Governance Committee will be $5,000"
principal financial officer financial
"Senior Vice President, Finance and Principal Financial Officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change did Armata Pharmaceuticals (ARMP) disclose in this 8-K/A?
Armata Pharmaceuticals updated its prior disclosure to add Dr. Daniel Gilmer’s committee role. The amendment specifies his appointment to the Nominating and Corporate Governance Committee and related compensation details, while leaving all other aspects of his original Board appointment unchanged.
Which Board committee did Dr. Daniel Gilmer join at Armata Pharmaceuticals (ARMP)?
Dr. Daniel Gilmer was appointed to Armata Pharmaceuticals’ Nominating and Corporate Governance Committee. His committee service became effective on June 24, 2026, expanding his responsibilities beyond his initial role as a member of the company’s Board of Directors.
When did Dr. Gilmer’s committee appointment at Armata Pharmaceuticals (ARMP) become effective?
Dr. Gilmer’s appointment to the Nominating and Corporate Governance Committee became effective on June 24, 2026. The amended filing clarifies this effective date, which also governs how his cash retainer for committee service will be pro-rated for 2026.
How is Dr. Gilmer compensated for committee service at Armata Pharmaceuticals (ARMP)?
Dr. Gilmer will receive a $5,000 cash retainer for serving on the Nominating and Corporate Governance Committee. This payment follows Armata’s 2026 non-employee director compensation program and will be pro-rated from his June 24, 2026 effective appointment date.
Did Armata Pharmaceuticals (ARMP) change Dr. Gilmer’s overall director compensation in this amendment?
The amendment does not change Dr. Gilmer’s overall director compensation framework beyond adding the $5,000 committee retainer. It confirms that he participates in the non-employee director compensation program described in the April 27, 2026 proxy statement for the 2026 annual meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates